| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MRNA | Common Stock | Sale | -$262K | -1.44K | -13.04% | $181.50 | 9.62K | Jun 1, 2021 | See Footnote | F1, F2, F3 |
| transaction | MRNA | Common Stock | Sale | -$384K | -2.1K | -21.85% | $182.58 | 7.52K | Jun 1, 2021 | See Footnote | F1, F3, F4 |
| transaction | MRNA | Common Stock | Sale | -$602K | -3.28K | -43.62% | $183.61 | 4.24K | Jun 1, 2021 | See Footnote | F1, F3, F5 |
| transaction | MRNA | Common Stock | Sale | -$763K | -4.14K | -97.64% | $184.36 | 100 | Jun 1, 2021 | See Footnote | F1, F3, F6 |
| transaction | MRNA | Common Stock | Sale | -$18.5K | -100 | -100% | $185.27 | 0 | Jun 1, 2021 | See Footnote | F1, F3 |
| transaction | MRNA | Common Stock | Sale | -$1.66M | -9K | -0.14% | $183.90 | 6.28M | Jun 2, 2021 | Direct | F7 |
| transaction | MRNA | Common Stock | Gift | -2K | -0.03% | 6.28M | Jun 2, 2021 | Direct | F8, F9 | ||
| holding | MRNA | Common Stock | 7.39M | Jun 1, 2021 | See Footnote | F10 | |||||
| holding | MRNA | Common Stock | 9.05M | Jun 1, 2021 | See Footnote | F11 |
| Id | Content |
|---|---|
| F1 | This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. |
| F2 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $180.93 to $181.87. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F3 | These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |
| F4 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $181.96 to $182.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F5 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $183.00 to $184.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F6 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $184.04 to $184.97. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| F7 | This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020. |
| F8 | The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020, as amended December 23, 2020. |
| F9 | The reported disposition represents a bona fide charitable gift made by the reporting person. |
| F10 | These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |
| F11 | These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. |